Hemab Therapeutics Holdings, Inc. (COAG)

NASDAQ: COAG · Real-Time Price · USD

25.34

-8.66 (-25.47%)

At close: May 4, 2026, 4:00 PM EDT

25.00

-0.34 (-1.34%)

After-hours: May 4, 2026, 7:28 PM EDT

COAG Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	10.49	8.97
Research & Development	59.63	41.41
Operating Expenses	70.12	50.38
Operating Income	-70.12	-50.38
Interest & Investment Income	1.97	3.74
Other Non Operating Income (Expenses)	4.01	-1.88
Pretax Income	-64.14	-48.52
Income Tax Expense	-0.23	0.19
Net Income	-63.91	-48.71
Net Income to Common	-63.91	-48.71
Shares Outstanding (Basic)	0	0
Shares Outstanding (Diluted)	0	0
EPS (Basic)	-1486.35	-1132.72
EPS (Diluted)	-1486.35	-1132.72
Free Cash Flow	-61.49	-45.87
Free Cash Flow Per Share	-1430.02	-1066.84
EBITDA	-69.82	-50.14
D&A For EBITDA	0.3	0.25
EBIT	-70.12	-50.38

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q